H. Taniguchi

phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study

Background Trifluridine/tipiracil (FTD/TPI) showed survival benefit as monotherapy and in combination with bevacizumab (BEV) in the la...

K. Yamazaki ;

Toshiki Masuishi ;

T. Tsushima ;

K. Muro ;

H. Yasui ;

Kazuki Mori , MD;

H. Taniguchi ;

07/01/2019

Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study

Background Treatment of refractory metastatic colorectal cancer (mCRC) with trifluridine/tipiracil yields some survival benefits. Trifluridine/tipiracil combined with be...

S. Hamauchi ;

K. Yamazaki ;

Toshiki Masuishi ;

T. Tsushima ;

K. Muro ;

H. Yasui ;

Kazuki Mori , MD;

H. Taniguchi ;

T. Kawakami ;

Y. Onozawa ;

K. Honda ;

06/27/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

H. Taniguchi

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products